Richard F. Arrendale

TL;DR: A novel small molecule, MSX-122, is developed that is a partial CXCR4 antagonist without mobilizing stem cells, which can be safer for long-term blockade of metastasis than other reported CX CR4 antagonists.

TL;DR: The authors show that the drug efficiently inhibits the RNA polymerase of canine distemper virus (CDV), which is closely related to the measles virus and causes lethal, measles-like disease in ferrets, and suggest that this drug may be useful in the future for preemptive treatment of unprotected human contacts of measles cases.

TL;DR: A de novo hit-to-lead effort involving the redesign of benzimidazole-containing antagonists of the CXCR4 receptor resulted in the discovery of a novel series of 1,2,3,4-tetrahydroisoquinoline (TIQ) analogues, which show good potencies and low metabolic liability potential.

TL;DR: 2o (ERDRP-00519), a potent inhibitor of MeV with an aqueous solubility of approximately 60 μg/mL, shows a 10-fold exposure increase in the rat model relative to 2, displays near dose proportionality in the range of 10-50 mg/kg, and exhibits good oral bioavailability.

TL;DR: The novel synthetic curcumin analog EF31 is efficacious in inhibiting the growth of Tu212 xenograft tumors and may be useful for treating head and neck squamous cell carcinoma.